Trending
athenahealth Launches athenaPatient MCP to Bridge Official Patient Records into Anthropic’s Claude Putin gives Russian companies permission to use foreign data centers after Ukraine drone strikes Samsung SDS breaks ground on Gumi AI Data Center in South Korea SpaceXAI launching two additional data center campuses in Mississippi to further expand Colossus 2 Fireworks contracts 5MW of Nvidia Blackwell Ultra capacity at Era4 data center in UK California Resources and Bloom Energy eye 1GW of fuel cells across California to power data centers and other offtakers Why Regulatory Flexibility Demands Decision-Ready Clinical Evidence Aramco acquires 49% stake in Saudi Arabia’s Humain Nevada ISP owner pleads guilty to embezzling more than $7.8m from Internet buildout project Cellnex signs €375m loan with EIB to support rollout of 5G infrastructure TailorMed Secures Majority Private Equity Investment: Expanding AI-Driven Pharmacy Access AI’s Expansion Hits the Limits of Local Power SpaceX in talks to buy EchoStar’s Boost Mobile – report CIO Podcast – Episode 125: High Reliability vs AI Adoption with Renu Sara Nargund Cloud Revenue Hits $168B as AI Capacity Expands

BioStack Raises $9.5M | Ayble Health Raises $16M Series A

Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.. BioStack Raises $9.5M to Turn Global Hospital Data into Multimodal Training Datasets for Medical AI. Y Combinator Startup Transforms 100 Million Fragmented Patient Records Into Multimodal Training Data and Reinforcement Learning Environments for Medical AI Agents.

BioStack, a healthcare technology company, announced today that it’s launching a data infrastructure network to power the next era of medicine. It spans a global footprint across the U.S., India, Brazil, and Argentina with over 100 million de-identified patient records. By connecting fragmented clinical information, BioStack gives AI and biotech companies the high-quality data needed to train models that understand how disease unfolds, how treatments work, and what drives patient outcomes..

The company also announced $9.5 million in seed funding led by Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, and Y Combinator. The round will support BioStack’s continued expansion across the United States and international markets, development of its technology platform, and growth of its engineering and research teams..

Today, patient histories and other clinical data are often fragmented across hospitals, providers, and technology systems, leaving clinicians without a complete picture of a patient’s treatment. BioStack creates workflows that bring together clinical information across disparate health systems and geographies.

Connecting notes, labs, imaging, medications, treatments, and outcomes, BioStack provides a more comprehensive view of the patient and informs population-level and hospital-level discovery.. “Collecting every event linked to each patient enables a view of what happens at each stage of a patient’s journey,” said Sanat Mishra, Co-Founder and CEO at BioStack….

Full release here, originally announced October 22nd, 2026.. Ayble Health Raises $16M Series A to Expand the Nation’s Most Clinically Validated Virtual Digestive Health Clinic. Led by Neon, the Oversubscribed-Round Accelerates Expansion Into AI Precision Digestive Healthcare and Autoimmune Health, Driven by Rapid Scaling Across National Health Plans, Jumbo Employers, and Major Benefit Platforms.

Ayble Health, the nation’s leading AI-enabled virtual multidisciplinary GI clinic, today announced the close of a $16 million oversubscribed Series A round led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx, Accomplice, and several individual strategic investors. The round brings Ayble’s total capital raised to over $27 million..

Undertreated, Underserved, and Enormously Costly. Digestive and autoimmune conditions are among the most common, costly, and under-addressed chronic diseases in the country. GI conditions alone affect more than 70 million Americans and drive $136 billion in annual U.S. healthcare spending, more than the total cost of diabetes or heart disease, while nearly 70% of U.S. counties lack a single practicing gastroenterologist.

The two categories are also clinically intertwined: a 2025 study spanning more than 141 million patients found inflammatory bowel disease (IBD) associated with 24 distinct autoimmune comorbidities, underscoring the need for a care model built to treat patients across both conditions.. Meeting this dual burden requires a care model that can adapt to each patient’s overlapping conditions rather than treating them in isolation.

This new capital will be used to advance Ayble’s proprietary AI+clinician precision care model, deepening data-driven personalization for patient engagement, enrollment, and care delivery. Additionally, the company will leverage its proven multidisciplinary model and data infrastructure to expand beyond its core gastrointestinal (GI) footprint into adjacent complex therapeutic areas, starting with autoimmune conditions….

Full release here, originally announced September 17th, 2026.. . Get Fresh Healthcare & IT Stories Delivered Daily. Join thousands of your healthcare & HealthIT peers who subscribe to our daily newsletter..

We respect your privacy and will never sell or give out your contact information

 

Join the conversation

Your email address will not be published. Required fields are marked *